Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory to Standard Therapies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07825389
What this trial is testing

C-CAR168 in Participants With Progressive Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
AbelZeta Inc. 119
Not applicableEnded earlyNCT06455475
What this trial is testing

Derm-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone

Who this might be right for
Diabetic Foot Ulcer
Capsicure, LLC 120
Early research (Phase 1)Study completedNCT01346358
What this trial is testing

IMC-CS4 in Subjects With Advanced Solid Tumors

Who this might be right for
Neoplasms
Eli Lilly and Company 52
Early research (Phase 1)Study completedNCT01340040
What this trial is testing

Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects

Who this might be right for
CancerAdvanced Solid Malignancies
AstraZeneca 10
Not applicableStudy completedNCT00230243
What this trial is testing

Historical Control Study of Refractory IFI or Patients Intolerant to Standard Antifungal Therapy in Patients With Invasive Fungal Infections (Study P02387)

Who this might be right for
Infection, Invasive Fungal
Merck Sharp & Dohme LLC 330
Testing effectiveness (Phase 2)Study completedNCT01421186
What this trial is testing

A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
MorphoSys AG 91
Not applicableWithdrawnNCT02347462
What this trial is testing

Bilevel Positive Airway Pressure (BiPAP) for the Treatment of Moderate to Severe Acute Asthma Exacerbations

Who this might be right for
AsthmaStatus Asthmaticus
University of British Columbia
Not applicableEnded earlyNCT00358098
What this trial is testing

Study to Determine the Utility of FES-PET and FDG-PET in the Prediction of Response to Hormone Therapy in Women With Estrogen Positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
AHS Cancer Control Alberta 51
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07077564
What this trial is testing

The Efficacy of TROP2-ADC in Advanced Extrapulmonary High-Grade Neuroendocrine Neoplasms Failure of Standard Therapy

Who this might be right for
Neuroendocrine Neoplasms (Tumours)
Second Affiliated Hospital, Zhejiang University, School of Medicine 35
Large-scale testing (Phase 3)Study completedNCT00588406
What this trial is testing

Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.

Who this might be right for
Asthma
Northwell Health 95
Early research (Phase 1)Study completedNCT01014936
What this trial is testing

First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors

Who this might be right for
Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available
EMD Serono 149
Testing effectiveness (Phase 2)UnknownNCT00081549
What this trial is testing

Aroplatin and Gemcitabine in Patients With Advanced Pancreatic Cancer Resistant to Standard Therapies

Who this might be right for
Pancreatic Neoplasms
Aronex Pharmaceuticals 111
Testing effectiveness (Phase 2)Study completedNCT00416624
What this trial is testing

Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy

Who this might be right for
AnemiaLeukemiaLymphoma+4 more
Mayo Clinic 239
Testing effectiveness (Phase 2)Active Not RecruitingNCT05547061
What this trial is testing

A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy

Who this might be right for
Prostate CancermCRPC
Cellbion Co., Ltd. 91
Early research (Phase 1)Study completedNCT02043847
What this trial is testing

TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)

Who this might be right for
Multiple Myeloma, RelapsedMultiple Myeloma, Refractory to Standard Treatment
University of Illinois at Chicago 12
Large-scale testing (Phase 3)Ended earlyNCT00000730
What this trial is testing

Comparison of Three Treatments for Pneumocystis Pneumonia in AIDS Patients

Who this might be right for
Pneumonia, Pneumocystis CariniiHIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 240
Large-scale testing (Phase 3)Active Not RecruitingNCT05263934
What this trial is testing

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

Who this might be right for
Eosinophilic Granulomatosis With Polyangiitis
GlaxoSmithKline 163
Not applicableStudy completedNCT06592222
What this trial is testing

Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies

Who this might be right for
Multiple Myeloma
Pfizer 4
Testing effectiveness (Phase 2)Study completedNCT02464228
What this trial is testing

Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy

Who this might be right for
Relapsed or Refractory Peripheral T-Cell Lymphoma
Kura Oncology, Inc. 65
Testing effectiveness (Phase 2)UnknownNCT05029102
What this trial is testing

TAS-102 and Anlotinib in ≥3 Lines mGC

Who this might be right for
Gastric Cancer
Zhejiang University 45
Next Page